A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC — StellaPhase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
Trial locations(7 sites)
China
Beijing Cancer Hospital, Beijing, Beijing Municipality Guangdong Provincial People's Hospital, Guangzhou, Guangdong Henan Cancer Hospital, Zhengzhou, Henan JiangSu Cancer Hospital, Nanjing, Jiangsu Zhongshan Hospital, Fudan University, Shanghai, Shanghai Municipality West China Hospital,Sichuan University, Chengdu, Sichuan ZheJiang Cancer Hospital, Hangzhou, Zhejiang Last updated November 2021